A case of severe constipation is described in a 75-year- old cancer patient receiving methadone for pain. Her constipation was refractory to the current treatment and she suffered severe discomfort and cognitive impairment. Due to the severity of the clinical situation and after excluding mechanical obstruction, low doses of subcutaneous neostigmine were administered, having bowel movements with evacuation of stools in a few hours after its administration.
Discussion:
The results suggest that subcutaneous neostigmine could be an alternative choice in a group of selected patients with advanced cancer and opioid-induced constipation.
Get full access to this article
View all access options for this article.
References
1.
CurtisEB, KrechR, WalshTD. Common symptoms in patients with advanced cancer. J Palliat Care, 1991; 7:25–29.
2.
DalalS, Del FabbroE, BrueraE. Symptom control in palliative care—Part 1: Oncology as a paradigmatic example. J Palliat Care, 2006; 8:391–408.
3.
DroneyJ, RossJ, GrettonS, WelshK, SattoH, RileyJ. Constipation in cancer patients on morphine. Support Care Cancer, 2008; 16:453–459.
4.
RubialesAS, HernansanzS, GutiérrezC, del ValleML, FloresLA. Neostigmine for refractory constipation in advanced cancer patients. J Pain Symptom Manage, 2006; 32:204–205.
5.
ClemensKE, KlaschikE. Management of opioid-induced constipation in advanced illness: Focus on methylnaltrexone bromide. Ther Clin Risk Manag, 2010; 6:77–82.
6.
BrueraE, FadulN. Constipation and diarrhea. BrueraE, HigginsonI, RipamontiC, von GuntenC. Textbook of Palliative Medicine. London: Hodder Arnold, 2006; 554–570.
7.
KaufmanPN, KrevskyB, MalmudLS, MaurerAH, SomersMB, SiegelJA, FisherRS. Role of opiate receptors in the regulation of colonic transit. Gastroenterology, 1988; 94:1351–1356.
8.
SpillerR. Mechanisms of postoperative intestinal motor dysfunction. Curr Opin Gastroenterol, 2003; 2:103–105.
9.
PanchalSJ, Muller-SchwefeP, WurzelmannJ. Opioid-induced bowel dysfunction: Prevalence, pathophysiology and burden. Int J Clin Pract, 2007; 61:1181–1187.
10.
DaeninckPJ, BrueraE. Reduction in constipation and laxative requirements following opioid rotation to methadone: A report of four cases. J Pain Symptom Manage, 1999; 18:303–309.
11.
MercadanteS, CassucioA, FulfaroF, GroffL, BoffiR, VillariP, GebbiaV, RipamontiC. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: A prospective study. J Clin Oncol, 2001; 19:2898–2904.
12.
LarkinPJ, SykesNP, Centeno C EllershawJE, ElsnerF, EugeneB, GootjesJR, NabalM, NogueraA, RipamontiC, ZuccoF, ZuurmondWW. European Consensus Group on Constipation in Palliative Care: The management of constipation in palliative care: Clinical practice recommendations. Palliat Med, 2008; 22:796–807
13.
ThomasJ, KarverS, AustinG, ChamberlainBH, WattCK, SlatkinNE, StamblerN, KremerAB, IsraelRJ. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med, 2008; 358:2332–2243.
14.
ArpinoPA, ThompsonBT. Safety of enteral naloxone for the reversal of opioid- induced constipation in the intensive care unit. J Clin Pharm Ther, 2009; 34:171–175.
15.
ClemensKE, MikusG. Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: Review of efficacy and safety data in the treatment of patients experiencing chronic pain. Expert Opin Pharmacother, 2010; 11:297–310.
ChoiYS, BillingsJA. Opioid antagonists: A review of their role in palliative care, focusing on use in opioid-related constipation. J Pain Symptom Manage, 2002; 24:71–90.
18.
DonatiF, BevanD. Neuromuscular blocking agents. BarashP, CullenB, StoeltingR. Clinical Anesthesia, 5th. Philadelphia: Lippincott Williams and Wilkins, 2006; 421–452.
19.
ThomasMC, ErstadBL. Safety of enteral naloxone and i.v. neostigmine when used to relieve constipation. Am J Health Syst Pharm, 2003; 60:1264–1267.
20.
SetheeJ, DunnP. Neuromuscular blockade. DunnP. Clinical Anesthesia. Procedures of the Massachusetts General Hospital, 7th. Philadelphia: Lippincott Williams and Wilkins, 2000; 190–207
